PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Clinical Trial ID NCT01973660

Rank	Title	Journal	Year	PubWeight™‹?›
1	Comprehensive molecular portraits of human breast tumours.	Nature	2012	47.39
2	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	7.31
3	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.	Lancet Oncol	2011	7.10
4	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.	J Clin Oncol	2013	1.81
5	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.	Breast Cancer Res Treat	2012	1.29
6	Neoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implications.	Ther Adv Med Oncol	2014	0.75